# Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

> **NCT01253525** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 6 (actual)

## Conditions studied

- Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Ramucirumab (IMC-1121B )
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01253525
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253525, "Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01253525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*